Matthew Kurian, Physician at St. Elizabeth Healthcare, shared on LinkedIn: “TumorSight Risk recently received FDA 510(k) clearance, marking another step forward for AI in breast oncology. Importantly, this tool is currently intended for HR+/HER2− bre... [1994 chars]



Read Comments